Cover Image
Market Research Report

Acyl CoA Desaturase - Pipeline Review, H2 2020

Published by Global Markets Direct Product code 379067
Published Content info 53 Pages
Delivery time: 1-2 business days
Price
Back to Top
Acyl CoA Desaturase - Pipeline Review, H2 2020
Published: July 31, 2020 Content info: 53 Pages
Description

Summary:

According to the recently published report 'Acyl CoA Desaturase - Pipeline Review, H2 2020'; Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) pipeline Target constitutes close to 9 molecules.

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Stearoyl-CoA desaturase 1 is a protein encoded by the SCD gene. Stearoyl-CoA desaturase-1 plays an important enzyme in fatty acid metabolism. Alteration in SCD1 expression changes the fatty acid profile of these lipids and produces diverse effects on cellular function. High SCD1 expression is correlated with metabolic diseases such as obesity and insulin resistance, whereas low levels are protective against these metabolic disturbances. SCD1 is also involved in the regulation of inflammation and stress in distinct cell types, including B-cells, adipocytes, macrophages, endothelial cells, and myocytes. Complete loss of SCD1 expression has been implicated in liver dysfunction and several inflammatory diseases such as dermatitis, atherosclerosis, and intestinal colitis.

The report 'Acyl CoA Desaturase - Pipeline Review, H2 2020' outlays comprehensive information on the Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 6 respectively. Report covers products from therapy areas Gastrointestinal, Oncology, Metabolic Disorders, Central Nervous System, Genetic Disorders and Musculoskeletal Disorders which include indications Non-Alcoholic Steatohepatitis (NASH), Colorectal Cancer, Obesity, Breast Cancer, Diabetes, Fibrosis, Hepatocellular Carcinoma, Metastatic Renal Cell Carcinoma, Non Alcoholic Fatty Liver Disease (NAFLD), Parkinson's Disease, Prader-Willi Syndrome (PWS) and Steatohepatitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1)
  • The report reviews Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC2543TDB

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Overview
  • Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Companies Involved in Therapeutics Development
  • Daiichi Sankyo Co Ltd
  • Galmed Pharmaceuticals Ltd
  • Japan Tobacco Inc
  • Lipidio Pharmaceuticals Inc
  • Modulation Therapeutics Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Yumanity Therapeutics
  • Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Drug Profiles
  • Aramchol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Aramchol Meglumine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DSP-0692 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Dormant Products
  • Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Discontinued Products
  • Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indication, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Daiichi Sankyo Co Ltd, H2 2020
  • Pipeline by Galmed Pharmaceuticals Ltd, H2 2020
  • Pipeline by Japan Tobacco Inc, H2 2020
  • Pipeline by Lipidio Pharmaceuticals Inc, H2 2020
  • Pipeline by Modulation Therapeutics Inc, H2 2020
  • Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2020
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
  • Pipeline by Yumanity Therapeutics, H2 2020
  • Dormant Projects, H2 2020
  • Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
Back to Top